Contact Us

Engineering the Future of Liposomal Drug Delivery

Lipella’s proprietary platform delivers targeted treatment to the mucosa — unlocking new potential in oncology support, inflammation, and orphan diseases.

Learn About Us

Learn About Us

Learn About Us

Engineered for Precision

Designed for Mucosal Delivery

Built to treat diseases of the bladder, oral cavity, urethra, esophagus, and colon — where traditional therapies struggle to reach or stay effective.

Designed for Mucosal Delivery

Built to treat diseases of the bladder, oral cavity, urethra, esophagus, and colon — where traditional therapies struggle to reach or stay effective.

Targeted, Localized Treatment

Our liposomes deliver drugs directly to damaged tissue, maximizing impact while minimizing systemic side effects.

Targeted, Localized Treatment

Our liposomes deliver drugs directly to damaged tissue, maximizing impact while minimizing systemic side effects.

Accelerated Development Pathways

We repurpose proven drugs with new delivery methods, enabling faster, lower-risk development through the 505(b)(2) pathway.

Accelerated Development Pathways

We repurpose proven drugs with new delivery methods, enabling faster, lower-risk development through the 505(b)(2) pathway.

Our Mission

At the heart of our mission is a commitment to transform scientific breakthroughs into real-world impact.

We believe that every data point, every tissue sample, and every molecular insight has the potential to change lives.

Our team of scientists, clinicians, and innovators is dedicated to pushing the boundaries of what's possible in the lab. We partner with academic institutions, biotech leaders, and healthcare providers to translate laboratory research into meaningful therapies that improve patient outcomes and shape the future of medicine.

Lipella Pharmaceuticals Pipeline

Lipella
Pharmaceuticals
Pipeline

Lipella
Pharmaceuticals
Pipeline

About Pipeline

About Pipeline

About Pipeline

  • LP-10 | Oral Rinse

    Oral Lichen Planus

    An oral rinse for OLP — a painful, chronic, pre-malignant disease affecting 6–7 million Americans.

    IND-approved Phase 2a trial underway
    First cohort topline data reported
    Final cohort completed (H2 2025)

  • LP-10 | Intravesical

    Hemorrhagic Cystitis

    A bladder-delivered therapy for moderate to severe hemorrhagic cystitis — a condition with no FDA-approved treatments.

    Orphan Drug Designation by the FDA
    Positive Phase 2a results published in Journal of Urology
    NIH-funded early-stage research

  • LP-10 | Oral Rinse

    Oral Graft versus Host Disease

    An oral rinse targeting chronic oral GvHD — a rare, life-threatening complication post bone marrow transplant.

    FDA Orphan Drug Designation granted
    IND approved for Phase 2a trial (March 2024)
    Designed for localized, mucosal immunomodulation

  • LP-50 | Non-Muscle

    Invasive Bladder Cancer

    A novel intravesical immunotherapy using liposomal PD-1 inhibitors to treat bladder cancer with reduced systemic toxicity.

    Designed for local delivery of checkpoint inhibitors
    Targets tumor directly, minimizing side effects
    Preclinical data published at ASCO 2024

  • LP-10 | Oral Rinse

    Oral Lichen Planus

    An oral rinse for OLP — a painful, chronic, pre-malignant disease affecting 6–7 million Americans.

    IND-approved Phase 2a trial underway
    First cohort topline data reported
    Final cohort completed (H2 2025)

  • LP-10 | Intravesical

    Hemorrhagic Cystitis

    A bladder-delivered therapy for moderate to severe hemorrhagic cystitis — a condition with no FDA-approved treatments.

    Orphan Drug Designation by the FDA
    Positive Phase 2a results published in Journal of Urology
    NIH-funded early-stage research

  • LP-10 | Oral Rinse

    Oral Graft Versus Host Disease

    An oral rinse targeting chronic oral GvHD — a rare, life-threatening complication post bone marrow transplant.

    FDA Orphan Drug Designation granted
    IND approved for Phase 2a trial (March 2024)
    Designed for localized, mucosal immunomodulation

  • LP-50 | Non-Muscle

    Invasive Bladder Cancer

    A novel intravesical immunotherapy using liposomal PD-1 inhibitors to treat bladder cancer with reduced systemic toxicity.

    Designed for local delivery of checkpoint inhibitors
    Targets tumor directly, minimizing side effects
    Preclinical data published at ASCO 2024